Paul Quinn, CWTE Limited · 21 November 2026
Summary
Juventus will get its money. The rights issue now running offers up to 208,516,998 new shares at €0.96, one for every two held, raising up to €200.2m. It is guaranteed by Exor, the Agnelli family holding company, which owns 65.4% of the club and controls 78.3% of the votes. No bank is underwriting it. Citigroup and UniCredit are coordinating on a “best effort” basis precisely because Exor has promised to buy whatever nobody else does.
So the outcome is not in doubt. What matters is what this raise says about the business. My conclusion is that this is replacement capital, not growth capital. It restores the balance sheet to close to where it was before the last loss, and the next loss is already in the guidance.
The deal in numbers
| Authority | Delegation of up to €250m (Art. 2443 Italian Civil Code), granted 3 November 2026; about €200m exercised now, about €50m kept for later financial years |
| New shares | Up to 208,516,998, one for every two held |
| Price | €0.96 (28.36% discount to TERP on the 12 November reference price) |
| Gross proceeds | Up to €200,176,318.08 |
| Timetable | Rights traded 16–25 November; subscription closes 1 December; rights auction on Euronext Milan follows |
| Exor | About €131m pro rata (including a €60m advance paid 29 September), plus an unconditional backstop of up to about €69m |
| Banks | Citigroup and UniCredit, joint global coordinators, best efforts, no underwriting |
| Offering document | Exempt information document filed with CONSOB; no prospectus |
Working back from the stated discount gives an implied reference price of about €1.53. The share closed at €1.865 on 29 September, the day before the raise was announced. A year ago the club sold shares at €2.58 in an accelerated bookbuild, and in December 2025 Tether offered €2.66 a share for Exor’s stake. Exor’s board rejected that the next day.
Two points that have been widely misreported:
- There is no prospectus. Juventus used the exemptions in Regulation (EU) 2017/1129 and filed a shorter information document with CONSOB, alongside a related-party document on Exor’s guarantee. Disclosure is lighter than in the 2021 rights issue.
- Exor’s €60m is not extra money. It was paid in September as an advance and counts towards Exor’s circa €131m share of this tranche.
The market’s verdict was quick. On the first day of rights trading the rights fell as much as 42% to about €0.078, well below their theoretical value of €0.13–0.19. That points to minority holders selling rather than following.
Where the money goes
On the board’s own figures, the club needs about 45–50% of the €250m delegation, which is €112.5m–€125m, to rebuild capital this year and, to a lesser degree, next, assuming normal sporting results. That leaves €75m–€90m of this tranche with no stated use. Everything else in the release, from Vinovo to the J|Hotel to player registrations, comes under the heading “possible upgrades”. The board says it “has not defined the allocation of proceeds”.
My reading is that the surplus is a cushion against another season outside the Champions League. Boards and fans should treat it that way rather than as a transfer kitty.
Seven years, one pattern
This is the fifth equity raise since 2019:
| Raise | Type | Gross amount | Exor contribution |
|---|---|---|---|
| 2019/20 | Rights issue | ≈€300m | €191m |
| 2021 | Rights issue | ≈€400m | €255m |
| 2024 | Rights issue at €1.582 | €199.9m | €128m |
| Nov 2025 | Accelerated bookbuild at €2.58, no pre-emption | €97.8m | ≈€64m |
| Nov–Dec 2026 | Rights issue at €0.96 | Up to €200.2m | ≈€131m + backstop |
Add up the restated net losses from FY2019/20 to FY2025/26 (€92.5m, €226.8m, €239.3m, €123.7m, €199.2m, €58.1m and €66.0m) and you get about €1,006m. Add up the equity raised from 2019 to 2025 and you get about €998m. The two numbers are within €8m of each other.
That is the whole story in one comparison. Every euro shareholders put in has gone to cover a euro of losses. Consolidated equity at 30 June 2026 was €11.5m. Net financial debt was €331.1m, more than double the €153.0m left after the 2021 raise. Equity stood at €77.9m at 31 December 2025, just after the last raise; the €97.8m raised in November 2025 was used up within a single financial year.
Exor has put in about €638m of that €998m. After this deal its total since 2019 rises towards €770m, and to about €840m if it has to take up the full backstop.
What has improved
To be fair to the current management, the cost reset is real. Registered-player wages have fallen from €310.8m in FY2021/22 to €209.8m in FY2025/26, a cut of about a third, and operating costs fell by €42.1m last year alone. The wage bill is now about 50% of operating revenue, against 77% four years ago.
The trouble is that operating revenue has stalled at about €417m–€420m, amortisation is still about €125m–€150m, and the Champions League decides whether the year looks tolerable or terrible. UEFA club-competition revenue was €73.6m in FY2025/26 and €0.1m in FY2023/24, the year Juventus was barred from Europe. That year produced a €199.2m loss. FY2025/26 also included a one-off €22m IMG settlement; without it the loss would have been about €88m rather than €66m.
The UEFA dimension
This is the part most coverage has missed. On 30 June 2026 Juventus signed a three-year settlement agreement with UEFA’s Club Financial Control Body for breaching the football-earnings rule. The club’s press release sets an “unconditional” amount of €6.0m and further “conditional” amounts of up to €14m, and squad registration is restricted. According to Calcio e Finanza, citing official UEFA documents, the deficit for the first monitoring period is capped at €5m, rising to €60m only if the shortfall is covered by equity, and the 2027 target is break-even.
Read that again: equity is written into the compliance mechanism. Exor’s €60m arrived the day the accounts were approved. This rights issue is, in part, a regulatory payment.
The club has been here before. Its 2022 settlement was breached, and in July 2023 UEFA excluded Juventus from the Conference League and fined it €20m. A second breach of a settlement in four years would put European exclusion back on the table.
Control and the Tether question
Tether holds 11.5% of the capital but only 7.2% of the votes; Lindsell Train holds 6.2%. Gazzetta dello Sport reports that Tether will take up its rights. On this tranche that costs about €23.1m; the widely quoted €28.8m was calculated on the full €250m. Tether has not confirmed this itself, and it abstained on the accounts and on board appointments at the November meeting. It is behaving as a committed but dissenting minority.
On my calculations, if nobody but Exor subscribed, Exor’s stake would rise to about 76.9%. If Tether also follows, Exor ends at about 73.1%. In practice the outcome will be somewhere between 65.4% and 73%. Either way, the message to any would-be buyer is the one Exor gave Tether last December: not for sale.
One governance point for independent directors: Exor’s guarantee was handled as a related-party transaction. Economia-italia reports the backstop fee at €1.05m on a residual of up to about €69m, roughly 1.5%, lower than the 2.5% charged in 2024. The advisers to the company and to the related-party committee have not been named publicly. They should be.
The legacy issues
The Agnelli-era legal overhang is largely closed:
- The 10-point deduction and personal bans of 2023 have been served.
- The salary manoeuvre was settled with a €718,240 fine.
- In Rome, Agnelli and other former executives took plea bargains; Agnelli received 1 year 8 months, suspended.
- A separate strand on the FY2021/22 accounts was dismissed in June 2026.
The legacy that remains is financial: a lost European season, restated accounts, and a habit of returning to shareholders.
What to watch
- Guidance. In September 2025 the club guided to break-even by FY2026/27. Twelve months later it guided to another loss and negative cash flow in FY2026/27, with “progressive improvement” over the following two years. That is a slip of at least two years in one year.
- The table. After 11 rounds Juventus are 7th on 18 points, six behind 4th. The Europa League campaign is going well, but it is the Champions League that funds the plan.
- Management. Giovanni Carnevali is the third chief executive or general manager in about 18 months.
- The €50m. If it is used, will existing shareholders get pre-emption rights, or will it be another bookbuild without them?
- The result. Take-up figures are due after the subscription period closes on 1 December. The split between Exor, Tether, Lindsell Train and the market will show how much of this raise the minorities still believe in.
My conclusion
The raise does what it needs to do. It keeps Juventus solvent and within its UEFA and FIGC limits for roughly two seasons. It does not make the club self-financing. Unless the cost reset is matched by a return to the Champions League and real growth in operating revenue, I expect another call on shareholders by FY2027/28 or FY2028/29. Exor will almost certainly answer it. The question for Exor’s own shareholders is how long they will be content for it to keep doing so.
Methodology note: figures come from Juventus annual financial reports and press releases (including those of 29 September, 11 November and 12 November 2026), Borsa Italiana notices and named press reports, chiefly Calcio e Finanza, Gazzetta dello Sport, Reuters and Il Sole 24 Ore. Restated figures are used where the club restated after CONSOB’s 2022 findings. The implied reference price, Exor’s resulting stakes and the cumulative totals are my calculations. Prices and discounts for the 2019 and 2021 raises, and the backstop fee, were not verified against primary documents. Position as at 21 November 2026. Nothing here is investment advice.
Leave a Reply